Dr. Cowey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1202
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Alabama Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Texas Medical Branch School of MedicineClass of 2003
Certifications & Licensure
TX State Medical License 2009 - 2024
NC State Medical License 2006 - 2009
AL State Medical License 2005 - 2006- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
- Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1500 citationsAdjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance
The New England Journal of Medicine. 2017-09-10 - 306 citationsAdjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, contr...Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance
The Lancet. Oncology. 2020-11-01 - 43 citationsA phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante
Cancer. 2019-04-01
Press Mentions
Dallas Clinical Trial Explores Slowing Skin Cancer Recurrence with COVID-19 TechnologyApril 23rd, 2024- Dallas Clinical Trial Explores Slowing Skin Cancer Recurrence with COVID-19 TechnologyApril 23rd, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
